JW (Cayman) Therapeutics (HKG:2126) appointed Min Liu, the company's current CEO, as the board's chairman, effective March 13, according to a Friday filing with the Hong Kong bourse.
Liu succeeds Yiping James Li, who stepped down earlier as CEO and remained interim chairman to ensure a smooth transition for the business.
The company's shares were 8% higher at the end of trading.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。